Glucagon-like peptide 1 (GLP-1) analogues that initially had been developed as drugs to treat diabetes have shown good neuroprotective effects in animal models of PD (Li et al., 2016; Hölscher, 2020; Zhang and Holscher, 2020). Here, GCG is linked to Parkinson disease.